论文部分内容阅读
目的探讨甲氨蝶呤(MTX)联合环磷酰胺(CTX)治疗类风湿性关节炎(RA)的临床疗效和安全性。方法将50例活动期RA患者随机分为治疗组和对照组各25例。治疗组给予甲氨喋呤(MTX)+环磷酰胺(CTX);对照组给予甲氨喋呤(MTX)+来氟米特(LEF)。两组均治疗12周。观察两组治疗后的临床疗效和不良反应。结果治疗12周后,治疗组在关节肿胀、关节压痛、晨僵时间、ESR及CRP等临床和实验室指标的改善均优于对照组,差异均有统计学意义(P<0.05);治疗组不良反应少于对照组,差异有统计学意义(P<0.05)。结论 MTX联合CTX治疗RA临床疗效好,不良反应小,安全性高。
Objective To investigate the clinical efficacy and safety of methotrexate (MTX) combined with cyclophosphamide (CTX) in the treatment of rheumatoid arthritis (RA). Methods Fifty patients with active RA were randomly divided into treatment group (n = 25) and control group (n = 25). The treatment group was given methotrexate (MTX) + cyclophosphamide (CTX); the control group was given methotrexate (MTX) + leflunomide (LEF). Both groups were treated for 12 weeks. The clinical effects and adverse reactions of the two groups after treatment were observed. Results After 12 weeks of treatment, the improvement of clinical and laboratory indexes such as swollen joints, joint tenderness, morning stiffness, ESR and CRP in the treatment group were better than those in the control group (P <0.05). The treatment group Adverse reactions less than the control group, the difference was statistically significant (P <0.05). Conclusion MTX combined with CTX treatment of RA clinical efficacy, adverse reactions, high safety.